Cannabis Use DisorderNCT07218471
Cannabis Reduction and Functional Outcomes
A study testing CBT4CBT (Computerized Cognitive Behavioral Therapy), Motivational Interviewing and Contingency Management in people with Cannabis Use Disorder, run by Medical University of South Carolina at 1 site in United States.
Trial summary
This study evaluates the effects of cannabis use reduction among adults diagnosed with cannabis use disorder (CUD). Participants will undergo an 8-week intervention combining motivational interviewing, computerized cognitive behavioral therapy (CBT4CBT), and financial incentives for reduction in urinary cannabinoids. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cannabis Use Disorder
- What is being tested?
- CBT4CBT (Computerized Cognitive Behavioral Therapy), Motivational Interviewing and Contingency Management
- Type of treatment
- Lifestyle or therapy programme
- How many people
- 176 participants
- Where
- 1 siteUnited States
- Study dates
- 13 Mar 2026to 30 Jan 2030
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age 18+
- Urinary cannabinoid level ≥ 50 ng/mL
- DSM-5 diagnosis of CUD (mild, moderate, or severe)
- Willingness to attempt cannabis reduction
- Completion of Intake Visit
Who cannot join
- Serious medical/psychiatric conditions
- Pregnancy or breastfeeding
- Use of cannabis in past 30 days was for medical purposes only
- Discontinuation or reduction of cannabis use may exacerbate a pre-existing condition
- Cognitive or understanding difficulties, as evidenced by inability to pass informed consent quiz
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Medical University of South Carolina
Charleston, South Carolina, 29425
Kevin Branson, MA, ADC, MAC, 843-792-0493, bransonk@musc.edu
Rachel Tomko, PhD, 843-792-5447, tomko@musc.edu
About this study
Official title: Prospective Changes in Patient-reported and Objective Functioning Following Reduction of Cannabis Use
This study evaluates the effects of cannabis use reduction among adults diagnosed with cannabis use disorder (CUD). Participants will undergo an 8-week intervention combining motivational interviewing, computerized cognitive behavioral therapy (CBT4CBT), and financial incentives for reduction in urinary cannabinoids. The study aims to assess improvements in cannabis-related problems, sleep, cognitive performance, CUD severity, and quality of life.
- Conditions
- Cannabis Use Disorder
- Being tested
- CBT4CBT (Computerized Cognitive Behavioral Therapy), Motivational Interviewing, Contingency Management
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CBT4CBT (Computerized Cognitive Behavioral Therapy)Behavioural
Participants will receive one therapist-led motivational interviewing/goal setting session followed by 7 sessions of computerized CBT4CBT.
Motivational InterviewingBehavioural
Participants will receive one therapist-led motivational interviewing/goal setting session followed by 7 sessions of computerized CBT4CBT.
Contingency ManagementBehavioural
Patients will receive contingent reinforcers (financial incentives for reduction in urinary cannabinoids).
What is being measured
The primary outcome is the main question the study is designed to answer.
Cannabis-Related Problems
Rutgers Marijuana Problem Index (RMPI)- higher scores associated with worse outcomes.
Measured: Week 8 (end-of-treatment)
Secondary outcomes (9)
Total minutes of sleep per night
Measured via Fitbit Charge.
Measured: Week 8 (end-of-treatment)
Minutes of light sleep per night
Measured via Fitbit Charge.
Measured: Week 8 (end-of-treatment)
Minutes of rapid eye movement (REM) sleep per night
Measured via Fitbit Charge.
Measured: Week 8 (end-of-treatment)
Minutes of deep sleep per night
Measured via Fitbit Charge.
Measured: Week 8 (end-of-treatment)
Sleep efficiency rating
"Sleep score" as provided by Fitbit Charge. Range is 1-100 with higher scores indicating better sleep quality/efficiency.
Measured: Week 8 (end-of-treatment)
Rey Auditory Verbal Learning Test (Verbal Memory) Age-Adjusted Standard Score
NIH Toolbox assessment; Higher scores indicate better cognitive functioning in this domain.
Measured: Week 8 (end-of-treatment)
Face/Name Associative Memory Test (Visual Memory) Age-Adjusted Standard Score
NIH Toolbox assessment; Higher scores indicate better cognitive functioning in this domain.
Measured: Week 8 (end-of-treatment)
Oral Symbol Digit Test Age-Adjusted Standard Score
NIH Toolbox assessment; Higher scores indicate better cognitive functioning in this domain.
Measured: Week 8 (end-of-treatment)
Pattern Comparison Processing Speed Test (Processing Speed) Age-Adjusted Standard Score
NIH Toolbox assessment; Higher scores indicate better cognitive functioning in this domain.
Measured: Week 8 (end-of-treatment)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Oct 2025
- Study start13 Mar 2026
- Primary completion15 Sep 2029 (estimated)
- Study completion30 Jan 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cannabis Use DisorderStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 176 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Medical University of South Carolina
- Sponsor type
- University, hospital or other
- Collaborators
- National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
- Responsible party
- Principal investigator, Rachel Tomko, Medical University of South Carolina
- Investigators
- Rachel Tomko, PhD., Principal investigator, Medical University of South CarolinaErin McClure, PhD., Principal investigator, Medical University of South Carolina
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07218471
- Sponsor's protocol ID
- Pro00145652
- Other IDs
- NIDA R01 DA062443
- Status last verified
- Oct 2025
- First submitted
- 13 Oct 2025
- Last updated
- 19 Mar 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 19 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prospective Changes in Patient-reported and Objective Functioning Following Reduction of Cannabis Use
- ClinicalTrials.gov ID
- NCT07218471
- Acronym / sponsor ID
- Pro00145652
- Conditions
- Cannabis Use Disorder
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 176 participants (estimated)
- Lead sponsor
- Medical University of South CarolinaUniversity, hospital or other
- Collaborators
- National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
- Study start
- 13 Mar 2026 (actual)
- Primary completion
- 15 Sep 2029 (estimated)
- Study completion
- 30 Jan 2030 (estimated)
- First posted
- 20 Oct 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study evaluates the effects of cannabis use reduction among adults diagnosed with cannabis use disorder (CUD). Participants will undergo an 8-week intervention combining motivational interviewing, computerized cognitive behavioral therapy (CBT4CBT), and financial incentives for reduction in urinary cannabinoids. The study aims to assess improvements in cannabis-related problems, sleep, cognitive performance, CUD severity, and quality of life.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Age 18+
- Urinary cannabinoid level ≥ 50 ng/mL
- DSM-5 diagnosis of CUD (mild, moderate, or severe)
- Willingness to attempt cannabis reduction
- Completion of Intake Visit
Key exclusion criteria (5 listed)
- Serious medical/psychiatric conditions
- Pregnancy or breastfeeding
- Use of cannabis in past 30 days was for medical purposes only
- Discontinuation or reduction of cannabis use may exacerbate a pre-existing condition
- Cognitive or understanding difficulties, as evidenced by inability to pass informed consent quiz
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CBT4CBT (Computerized Cognitive Behavioral Therapy)Participants will receive one therapist-led motivational interviewing/goal setting session followed by 7 sessions of computerized CBT4CBT. | Behavioural | – |
| Motivational InterviewingParticipants will receive one therapist-led motivational interviewing/goal setting session followed by 7 sessions of computerized CBT4CBT. | Behavioural | – |
| Contingency ManagementPatients will receive contingent reinforcers (financial incentives for reduction in urinary cannabinoids). | Behavioural | – |
Primary outcome
Cannabis-Related Problems
Time frame: Week 8 (end-of-treatment)
Rutgers Marijuana Problem Index (RMPI)- higher scores associated with worse outcomes.
9 secondary outcomes
Total minutes of sleep per night
Time frame: Week 8 (end-of-treatment)
Minutes of light sleep per night
Time frame: Week 8 (end-of-treatment)
Minutes of rapid eye movement (REM) sleep per night
Time frame: Week 8 (end-of-treatment)
Minutes of deep sleep per night
Time frame: Week 8 (end-of-treatment)
Sleep efficiency rating
Time frame: Week 8 (end-of-treatment)
Rey Auditory Verbal Learning Test (Verbal Memory) Age-Adjusted Standard Score
Time frame: Week 8 (end-of-treatment)
Face/Name Associative Memory Test (Visual Memory) Age-Adjusted Standard Score
Time frame: Week 8 (end-of-treatment)
Oral Symbol Digit Test Age-Adjusted Standard Score
Time frame: Week 8 (end-of-treatment)
Pattern Comparison Processing Speed Test (Processing Speed) Age-Adjusted Standard Score
Time frame: Week 8 (end-of-treatment)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Mar 2026.
Related trials for Cannabis Use Disorder
RecruitingPhase 3
Efficacy of PP-01 in Mitigating Cannabis Withdrawal Symptoms in Adults With Cannabis Use Disorder
Cannabis Withdrawal
Active, not recruitingObservational study
Cannabis Use and Outcomes in Black and White Patients With Cancer
Cancer
Recruiting
MATAspire: Mental Health Awareness Tailored App for Substance Prevention and Integrated Resilience Education
Alcohol Use, Cannabis Use
RecruitingObservational study
Study of an Oral Fluid Testing Approach
Cannabis Use, Cannabis Intoxication
Not yet recruitingEarly Phase 1
Research Investigating Drug Effects-2 (RiDE-2)
Cannabis Use, Substance Use Disorder (SUD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Rachel Tomko, PhD. principal investigator
Medical University of South Carolina
Erin McClure, PhD. principal investigator
Medical University of South Carolina
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing CBT4CBT (Computerized Cognitive Behavioral Therapy), Motivational Interviewing and Contingency Management in people with Cannabis Use Disorder, run by Medical University of South Carolina at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 19 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Rachel Tomko, PhD ((843) 792-5447, tomko@musc.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cannabis-Related Problems (time frame: Week 8 (end-of-treatment)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Mar 2026.